Aclarion (ACON) announced plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet (RDNT) affiliates in both states and are driven by the increased availability of MR Spectroscopy and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACON:
- Aclarion Inc trading halted, volatility trading pause
- Aclarion announces first commercial agreement with Scripps Health in San Diego
- Aclarion, Inc. Adjourns Special Meeting for More Votes
- Aclarion receives U.S. patent on expanded applications of MRS data processing
- Aclarion announces Northwestern Medicine as first CLARITY trial site